Literature DB >> 31444238

Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.

Michael Toss1, Islam Miligy2, Kylie Gorringe3, Karuna Mittal4, Ritu Aneja4, Ian Ellis2, Andrew Green2, Emad Rakha2.   

Abstract

AIMS: Cathepsin V (CTSV/CTSL2) is a lysosomal cysteine proteinase and plays a role in extracellular matrix degradation. It is associated with poor prognosis in invasive breast cancer (IBC), but its role in breast ductal carcinoma in situ (DCIS) remains unclear. In this study, we aimed to evaluate the prognostic significance of CTSV in DCIS.
METHODS: CTSV protein expression was immunohistochemically assessed in a well-characterised and annotated cohort of DCIS comprising pure DCIS (n=776) and DCIS coexisting with IBC (n=239). CTSV expression was analysed in tumour cells and surrounding stroma, including its association with clinicopathological parameters and outcome.
RESULTS: In pure DCIS, high CTSV expression was observed in 29% of epithelial tumour cells and 20% of surrounding stroma. High expression in both components was associated with features of poor prognosis including higher nuclear grade, hormone receptor negativity and HER2 positivity. In addition, stromal CTSV expression was associated with larger DCIS size, comedo-type necrosis and high proliferation index. DCIS associated with IBC showed higher CTSV expression than pure DCIS either within the epithelial tumour cells or surrounding stroma (p<0.0001 and p=0.001, respectively). In DCIS/IBC, CTSV expression was higher in the invasive component than DCIS component either in tumour cells or surrounding stroma (both p<0.0001). CTSV stromal expression was associated with invasive recurrence independent of other prognostic factors in patients treated with breast conserving surgery (HR=3.0, p=0.005).
CONCLUSION: High expression of CTSV is associated with poor outcome in DCIS and is a potential marker to predict DCIS progression to invasive disease. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  CTSV; DCIS; proteolysis; recurrence; stroma

Mesh:

Substances:

Year:  2019        PMID: 31444238     DOI: 10.1136/jclinpath-2019-205939

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

Review 1.  Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery.

Authors:  Daan G J Linders; Okker D Bijlstra; Laura C Fallert; Denise E Hilling; Ethan Walker; Brian Straight; Taryn L March; A Rob P M Valentijn; Martin Pool; Jacobus Burggraaf; James P Basilion; Alexander L Vahrmeijer; Peter J K Kuppen
Journal:  Mol Imaging Biol       Date:  2022-08-24       Impact factor: 3.484

Review 2.  Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression.

Authors:  Gemma M Wilson; Phuong Dinh; Nirmala Pathmanathan; J Dinny Graham
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-05-14       Impact factor: 2.698

Review 3.  Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.

Authors:  Valeria De Pasquale; Anna Moles; Luigi Michele Pavone
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

4.  A transcriptomic study for identifying cardia- and non-cardia-specific gastric cancer prognostic factors using genetic algorithm-based methods.

Authors:  Junyi Xin; Yanling Wu; Xiaowei Wang; Shuwei Li; Haiyan Chu; Meilin Wang; Mulong Du; Zhengdong Zhang
Journal:  J Cell Mol Med       Date:  2020-07-10       Impact factor: 5.310

5.  Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen.

Authors:  Juho J Miettinen; Romika Kumari; Gunnhildur Asta Traustadottir; Maiju-Emilia Huppunen; Philipp Sergeev; Muntasir M Majumder; Alexander Schepsky; Thorarinn Gudjonsson; Juha Lievonen; Despina Bazou; Paul Dowling; Peter O Gorman; Ana Slipicevic; Pekka Anttila; Raija Silvennoinen; Nina N Nupponen; Fredrik Lehmann; Caroline A Heckman
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

6.  Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer.

Authors:  Naphannop Sereesongsaeng; Sara H McDowell; James F Burrows; Christopher J Scott; Roberta E Burden
Journal:  Breast Cancer Res       Date:  2020-12-09       Impact factor: 6.466

7.  High CTSL2 expression predicts poor prognosis in patients with lung adenocarcinoma.

Authors:  Junnian Song; Jindong Jiang; Na Wei; Zongsheng Duan; Gang Wang; Weiyun Pan
Journal:  Aging (Albany NY)       Date:  2021-09-23       Impact factor: 5.682

8.  Glycosylated Cathepsin V Serves as a Prognostic Marker in Lung Cancer.

Authors:  Lewei Yang; Qi Zeng; Yun Deng; Yeqing Qiu; Wei Yao; Yifeng Liao
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

9.  Praeruptorin B Mitigates the Metastatic Ability of Human Renal Carcinoma Cells through Targeting CTSC and CTSV Expression.

Authors:  Chia-Liang Lin; Tung-Wei Hung; Tsung-Ho Ying; Chi-Jui Lin; Yi-Hsien Hsieh; Chien-Min Chen
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

Review 10.  Exosomes: Insights from Retinoblastoma and Other Eye Cancers.

Authors:  Kashmiri Lande; Jitesh Gupta; Ravi Ranjan; Manjari Kiran; Luis Fernando Torres Solis; Arturo Solís Herrera; Gjumrakch Aliev; Roy Karnati
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.